Relapse and survival after CD19 CAR T-cell reinfusion for relapse prevention. (A) CIR or death from the time of assessment of response to CARTr among patients with a CR or NR to CARTr. Data were censored at the time of HSCT, other anticancer therapy while in remission, or last follow-up. (B) OS from the time of assessment of response to CARTr among patients with a CR or NR to CARTr. Data were censored at the time of last follow-up with a data cutoff of 1 July 2021. NR, nonresponse.